Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Torres

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Life Science Alliance|January 18, 2022
Malaria abrogates O'nyong-nyong virus pathologies by restricting virus infection in nonimmune cellsAnthony Torres-Ruesta, Teck-Hui Teo, Yi-Hao Chan, et al.
Frontiers in Immunology|June 2, 2020
Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus InfectionYi-Hao Chan, Teck-Hui Teo, Anthony Torres-Ruesta, et al.
Journal of Medical Virology|May 22, 2023
Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infectionSiew-Wai Fong, Yun Shan Goh, Anthony Torres-Ruesta, et al.
Nature Communications|October 20, 2025
Mosquito salivary sialokinin reduces monocyte activation and chikungunya virus-induced inflammation via neurokinin receptorsSiew-Wai Fong, Jeslin J L Tan, Vaishnavi Sridhar, et al.
Ebiomedicine|July 26, 2020
Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severitySiti Naqiah Amrun, Cheryl Yi-Pin Lee, Bernett Lee, et al.
Nature Communications|June 3, 2020
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patientsChek Meng Poh, Guillaume Carissimo, Bei Wang, et al.
Clinical & Translational Immunology|February 25, 2021
Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variantCheryl Yi-Pin Lee, Siti Naqiah Amrun, Rhonda Sin-Ling Chee, et al.
Journal of Clinical Immunology|October 30, 2021
Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant InfectionSiew-Wai Fong, Nicholas Kim-Wah Yeo, Yi-Hao Chan, et al.
EMBO Molecular Medicine|May 7, 2021
Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2Yi-Hao Chan, Siew-Wai Fong, Chek-Meng Poh, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Life Science Alliance|January 18, 2022
Malaria abrogates O'nyong-nyong virus pathologies by restricting virus infection in nonimmune cellsAnthony Torres-Ruesta, Teck-Hui Teo, Yi-Hao Chan, et al.
Frontiers in Immunology|June 2, 2020
Longitudinal [18F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus InfectionYi-Hao Chan, Teck-Hui Teo, Anthony Torres-Ruesta, et al.
Journal of Medical Virology|May 22, 2023
Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infectionSiew-Wai Fong, Yun Shan Goh, Anthony Torres-Ruesta, et al.
Nature Communications|October 20, 2025
Mosquito salivary sialokinin reduces monocyte activation and chikungunya virus-induced inflammation via neurokinin receptorsSiew-Wai Fong, Jeslin J L Tan, Vaishnavi Sridhar, et al.
Ebiomedicine|July 26, 2020
Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severitySiti Naqiah Amrun, Cheryl Yi-Pin Lee, Bernett Lee, et al.
Nature Communications|June 3, 2020
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patientsChek Meng Poh, Guillaume Carissimo, Bei Wang, et al.
Clinical & Translational Immunology|February 25, 2021
Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variantCheryl Yi-Pin Lee, Siti Naqiah Amrun, Rhonda Sin-Ling Chee, et al.
Journal of Clinical Immunology|October 30, 2021
Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant InfectionSiew-Wai Fong, Nicholas Kim-Wah Yeo, Yi-Hao Chan, et al.
EMBO Molecular Medicine|May 7, 2021
Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2Yi-Hao Chan, Siew-Wai Fong, Chek-Meng Poh, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Pageof 5